Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

580 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Taylor AM, McKeown J, Dimitriou F, Jacques SK, Zimmer L, Allayous C, Yeoh HL, Haydon A, Ressler JM, Galea C, Woodford R, Kahler K, Hauschild A, Festino L, Hoeller C, Schwarze JK, Neyns B, Wicky A, Michielin O, Placzke J, Rutkowski P, Johnson DB, Lebbe C, Dummer R, Ascierto PA, Lo S, Long GV, Carlino MS, Menzies AM. Taylor AM, et al. Among authors: long gv. Eur J Cancer. 2024 Mar;199:113561. doi: 10.1016/j.ejca.2024.113561. Epub 2024 Jan 20. Eur J Cancer. 2024. PMID: 38278009
Treatment of melanoma brain metastases: a new paradigm.
Carlino MS, Fogarty GB, Long GV. Carlino MS, et al. Among authors: long gv. Cancer J. 2012 Mar-Apr;18(2):208-12. doi: 10.1097/PPO.0b013e31824b2890. Cancer J. 2012. PMID: 22453023 Review.
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, Egberts F, Hauschild A, Kashani-Sabet M, Goldinger SM, Dummer R, Long GV, McArthur G, Scherag A, Sucker A, Schadendorf D. Zimmer L, et al. Among authors: long gv. J Clin Oncol. 2012 Jul 1;30(19):2375-83. doi: 10.1200/JCO.2011.41.1660. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614973 Free PMC article.
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Long GV, et al. Lancet Oncol. 2012 Nov;13(11):1087-95. doi: 10.1016/S1470-2045(12)70431-X. Epub 2012 Oct 8. Lancet Oncol. 2012. PMID: 23051966 Clinical Trial.
BRAF inhibitor activity in V600R metastatic melanoma.
Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV. Klein O, et al. Among authors: long gv. Eur J Cancer. 2013 Mar;49(5):1073-9. doi: 10.1016/j.ejca.2012.11.004. Epub 2012 Dec 10. Eur J Cancer. 2013. PMID: 23237741
BRAF inhibitor activity in V600R metastatic melanoma--response.
Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV. Klein O, et al. Among authors: long gv. Eur J Cancer. 2013 May;49(7):1797-8. doi: 10.1016/j.ejca.2013.02.010. Epub 2013 Mar 13. Eur J Cancer. 2013. PMID: 23490649 No abstract available.
580 results